Multiplicity and Diversity of Plasmodium vivax Infections in a Highly Endemic Region in Papua New Guinea by Koepfli, Cristian et al.
Multiplicity and Diversity of Plasmodium vivax Infections
in a Highly Endemic Region in Papua New Guinea
Cristian Koepfli
1,2, Amanda Ross
1,2, Benson Kiniboro
3, Thomas A. Smith
1,2, Peter A. Zimmerman
4, Peter
Siba
3, Ivo Mueller
3,5,6, Ingrid Felger
1,2*
1Swiss Tropical and Public Health Institute, Basel, Switzerland, 2University of Basel, Basel, Switzerland, 3PNG Institute of Medical Research, Goroka, Papua New Guinea,
4Centre for Global Health and Disease, Case Western Reserve University, Cleveland, Ohio, United States of America, 5Walter and Eliza Hall Institute, Parkville, Victoria,
Australia, 6Barcelona Centre for International Health Research, Barcelona, Spain
Abstract
Plasmodium vivax is highly endemic in the lowlands of Papua New Guinea and accounts for a large proportion of the malaria
cases in children less than 5 years of age. We collected 2117 blood samples at 2-monthly intervals from a cohort of 268
children aged 1 to 4.5 years and estimated the diversity and multiplicity of P. vivax infection. All P. vivax clones were
genotyped using the merozoite surface protein 1 F3 fragment (msp1F3) and the microsatellite MS16 as molecular markers.
High diversity was observed with msp1F3 (HE=88.1%) and MS16 (HE=97.8%). Of the 1162 P. vivax positive samples, 74%
harbored multi-clone infections with a mean multiplicity of 2.7 (IQR=1–3). The multiplicity of P. vivax infection increased
slightly with age (P=0.02), with the strongest increase in very young children. Intensified efforts to control malaria can
benefit from knowledge of the diversity and MOI both for assessing the endemic situation and monitoring the effects of
interventions.
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Introduction
Malaria caused by Plasmodium vivax infection is increasingly
recognized as a public health burden. The worldwide population
at risk is estimated to be 2.85 billion, with high prevalences
observed in locations throughout Southeast Asia and the Pacific
[1]. Even though P. vivax epidemiology is less well studied and
understood compared to that of P. falciparum, it is thought that P.
vivax will present a greater challenge on the way to elimination of
malaria outside Africa. Papua New Guinea (PNG) presents a
variety of different climatic and ecological zones which have
differing levels of malaria transmission [2] with a high burden of P.
vivax in the tropical lowlands. The occurrence of high prevalence
and morbidity marks locations in PNG as suitable field sites for P.
vivax drug trials [3,4] and potentially also for future vaccine trials
[5].
In Maprik in northern PNG, both P. vivax and P. falciparum are
highly prevalent [6]. The incidence of P. vivax clinical episodes has
been shown to peak in the second year of life, while that of P.
falciparum increases until the fourth year [7,8]. Children between
one and five years are considered to be a target age-group for P.
vivax vaccine trials [5]. While previous studies have provided
baseline data on clinical incidence rates, epidemiological patterns
and the age-distribution of disease [8,9], genotyping data on
individual P. vivax clones describing their diversity and molecular
epidemiological parameters are scarce. For P. falciparum, the mean
number of concurrent infections per patient (multiplicity of
infection, MOI) has been used as one of several measures of the
impact of interventions. MOI is crucial to assess the risk that an
individual carries a drug resistant parasite and to evaluate levels of
inbreeding [10].
Here we describe the genetic diversity and multiplicity of
infection of a P. vivax population in an area of high malaria
prevalence in the Maprik District in PNG. Data were obtained
from children aged 1 to 4.5 years who were followed-up over 16
months [8]. We make use of two markers to genotype individual P.
vivax clones, one a microsatellite and the other a region of the msp1
gene, encoding the Merozoite Surface Protein 1. While the
microsatellite MS16 (located on NCBI contig XM_001615468.1)
is considered a neutral marker that has been used in a number of
population genetics studies [11,12], msp1 (XM_001614792)
encodes a potential vaccine candidate (reviewed in [13]) and its
diversity has been studied in different settings [14,15,16]. In a
previous study, the two markers showed robust PCR amplification
and high diversity with a risk of less than 1% that two clones share
the same two-loci haplotype [17].
Methods
Ethics statement
The cohort study was approved by institutional review boards
of the PNG Medical Research Advisory Committee (approvals
05.19 and 09.24), University Hospitals Case Medical Center
(Cleveland, Ohio USA), and the Ethikkommission beider Basel
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parents or legal guardians of each child.
Study site and design
The cohort study was conducted in the Ilaita area, Maprik
District, East Sepik Province, PNG between April 2006 and
August 2007. The study area has hyper- to holoendemic perennial
transmission with moderate seasonal variation [8,18,19,20]. P.
vivax infections are the most prevalent infection in young children
and remain frequent into adulthood, while P. falciparum is the
predominant infection in children over 4 years of age [6,21].
268 children aged 1 to 3 years at enrolment were followed-up
over a period of 16 months. As part of the cohort study, the
children were visited every two months with blood samples taken
at least for one and, for some surveys, on two consecutive days. In
the analysis presented here, only blood samples taken on the first
day were included. The prevalence of Plasmodium species by
microscopy in the study population was 44.3% for P. vivax, 32.6%
for P. falciparum and 4.2% for P. malariae [8]. Defining clinical
episodes as the presence of fever .37.5uC (axillary temperature
measured twice and a third time if the difference was above 0.3u)
or history of fever during the last 48 hours together with
parasitaemia observed by light microscopy, the clinical incidence
rates were 2.56 P. falciparum and 2.46 P. vivax episodes per child per
year [8]. Children presenting with parasitologically confirmed
malaria (i.e. positive blood slide or RDT) were treated with
Coartem. Details of the study have been published previously [8],
as well as genotyping data of the population of P. falciparum clones
in this cohort [22].
Species detection, genotyping and data analysis
Finger prick and venous blood samples were collected and DNA
was extracted as previously described [8]. The presence of P.
falciparum, P. vivax, P. ovale and P. malariae was detected by light
microscopy as well as by post-PCR Ligase Detection Reaction
(LDR) [8], a molecular method for the detection and species
identification of malaria parasites [23]. All samples which were P.
vivax positive by light microscopy or LDR plus 88 negative baseline
samples were selected for genotyping.
The selection of highly diverse molecular markers is crucial for
assessing MOI in molecular epidemiology studies. Based on our
previous results [17], we selected the polymorphic marker gene
msp1F3 and the microsatellite MS16 for genotyping. In contrast to
population genetic studies, where large numbers of neutral
markers of moderate to high diversity (e.g. microsatellites) are
generally analyzed, a small number of highly polymorphic markers
are ideal for tracking clones in epidemiological studies for two
reasons Where concurrent infections with several clones are
common construction of haplotypes combining data from several
PCR amplified markers is difficult. In addtion, when MOI is
defined as the maximum number of clones by any of the markers
typed, the risk of overestimating MOI due to PCR artefacts
increases with the number of markers analyzed, in particular for
microsatellite amplification where PCR artefacts caused by
polymerase slippage are of concern [24] (Tables A and B in Text
S1). Any highly polymorphic marker is suitable for studying the
epidemiology of multiple infections. As long as high diversity is
maintained, there is no need for selective neutrality.
In this molecular epidemiological study, the coding sequence
msp1F3 was chosen because it harbours a more complex repeat
structure than microsatellites. This has the advantage that PCR
artefacts due to slippage are rare for msp1F3. Our second marker
was MS16, a highly polymorphic microsatellite that lacks
dominant alleles.
PCR and capillary electrophoresis were performed with slight
modifications of the published protocol [17] to save costs and
labour time: a multiplex primary PCR was done with the primers
for the 2 markers msp1F3 and MS16 followed by individual nested
PCRs for msp1F3 and MS16. The primary PCR was done in a
volume of 20 ml containing 1 ml template DNA, 0.25 mM of each
primer (Eurofins MWG Operon), 0.3 mM dNTPs (Solis BioDyne),
2 mM MgCl2,2ml Buffer B (Solis BioDyne) and 5 U TaqFIREPol
(Solis BioDyne). As we expected low parasitemia in samples
negative by microscopy, 2 ml DNA instead of 1 ml were used for
the primary PCR. 1 ml primary PCR product was used as the
template for the nested PCR, which was performed in a volume of
20 ml containing 0.25 mM of each primer (Applied Biosystems),
0.2 mM dNTPs (Solis BioDyne), 2 mM MgCl2,2ml Buffer B
(Solis BioDyne) and 1.5 U TaqFIREPol (Solis BioDyne). The
forward primers for the nested PCR were labelled with fluorescent
dyes: 6-FAM for msp1F3, NED for MS16. Cycling conditions were
as follows: initial denaturation 95uC for 1 minute, then 30 cycles
(primary PCR) or 25 cycles (nested PCR) with 15 seconds
denaturation at 95uC, 30 seconds annealing at 59uC and
30 seconds elongation at 72uC plus a final elongation of 5 minutes
at 72uC. Subsequently, capillary electrophoresis was performed as
described [17].
The PCR data was analysed using the GeneMarkerH pro-
gramme version 1.85 (SoftGenetics). Based on experience from
preliminary studies, peaks above a cut off of 1000 units relative
fluorescent intensity (RFU) were considered true amplification
products, all peaks below this cut off were considered background
noise as well as lesser peaks in the vicinity of strong peaks reaching
40% (msp1F3) and 70% (MS16) of their height. Occasionally the
fluorescence intensity differed between plates or samples as
indicated by varying signal intensities of the commercial size
standard. To compensate for this technical shortfall, the standard
cut off value was lowered from 1000 to 300 RFU if signal
intensities of both sample peaks and size standard peaks were low
(generally below 1000 RFU). This practice was justified by a
greater agreement in positivity at both loci. As a consequence, the
proportion of samples positive only for a single marker dropped
from 12% to 10%. All samples were checked visually (after
blinding of samples) for stutter peaks thereby excluding one
msp1F3 and 25 MS16 samples from further analyses.
Author Summary
The parasite Plasmodium vivax is the second most frequent
cause of malaria in humans. In the Maprik area in lowland
Papua New Guinea, P. vivax and P. falciparum are
sympatric each with a prevalence of around 50%.
Longitudinal samples from 268 children aged 1 to 4.5
years over 16 months were collected. The 1162 blood
samples positive for P. vivax were genotyped for two size-
polymorphic molecular markers. A very high parasite
diversity was observed. The number of co-infecting
parasite clones per carrier (multiplicity) was nearly twice
as high for P. vivax as for P. falciparum despite the similar
prevalences of the species. The P. vivax multiplicity
increased with age, with the strongest increase in young
children below 1.5. This is likely to be a consequence of
fast acquisition of immunity against P. vivax malaria and
also of relapses, the release of long-lasting, silent liver
stages to the blood stream. This is the first dataset from a
highly endemic setting that presents data on a large
number of individual P. vivax clones genotyped with
highly diverse markers.
Plasmodium vivax in Papua New Guinea
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samples for both markers in duplicate. 80% of msp1F3 clones and
88% of MS16 clones were detected in both replicates (Tables C
and D in Text S1). An important reason for the imperfect
detection of clones is the low concentration of template DNA in
samples with scanty parasitemia, where partial amplification of all
templates seems to be governed by chance. In serial dilutions of
DNA in field samples, we have demonstrated this effect by
performing PCR amplification in triplicate for each dilution
(Tables E and F and Figures A and B in Text S1). At low DNA
concentrations, the allelic composition of a blood sample differed
between replicates with individual clones detected in an apparently
random fashion (out of several clones detected in undiluted DNA).
Data analysis
Alleles were grouped into bins of 3 base pairs, defined by the
expected size differences in the two markers: 3 base pairs (bp) for
the coding region of Pvmsp1 as well as for microsatellite MS16
harbouring a 3 bp repeat unit. When a single genotype was
observed with both markers, a blood sample was defined as single
clone infection. In multiple clone infections, the highest number of
clones observed for either marker defined the combined MOI of a
blood sample. We used the kappa statistic to describe agreement
between the molecular markers after correcting for chance
agreement.
The determination of MOI for single and double clone
infections was validated by genotyping a subset of samples with
12 additional markers. MOI=1 was confirmed in 67/92 (72.8%)
samples and MOI=2 in 31/32 (96.9%) samples (Tables A and B
in Text S1).
Although the distributions of MOI are skewed, we present the
mean MOI, a common measure, to allow comparisons with other
studies. We estimated the effect of age (at the time of the survey in
6 months age groups) and season on prevalence and MOI using
regression models. To account for multiple visits per child, we
included a random effect for child. The models were implemented
in STATA version 10 [25] and WinBUGS version 1.4 [26].
The genetic diversity of a given locus in a population is
expressed by the virtual heterozygosity HE, i.e. the probability that
two clones taken at random from the population carry different
alleles. HE was calculated using the formula
HE~
n
n{1
(1{
X
pi
2)
where n is the number of clones analysed and p is the frequency of
allele i. HE of msp1F3 and MS16 were determined by using only
the first P. vivax positive sample of each study participant; HE of
msp1F3/MS16 haplotypes by using the first single clone infection
per patient. This procedure prevents potential sampling bias due
to repetition of persisting clones from the same individual. Linkage
between markers was assessed using LIAN 3.5 [27]. Linkage
disequilibrium measured from only two markers cannot provide
information on inbreeding and was used only to provide evidence
that the markers occur independently of each other.
Results
Of the 2117 blood samples collected in cross sectional surveys,
1340 were genotyped since they were positive by microscopy or
LDR. Of the 88 microscopy and LDR negative samples that were
selected for genotyping, only 2 (2.3%) were positive. This low
proportion did not justify genotyping all negative samples.
Nested PCR for the two P. vivax genotyping markers provided
an amplification product from at least one marker from 1162
samples. msp1F3 PCR products were obtained from 1094 samples
MS16 PCR products from 1118 (Table 1). In 1050 samples
(90.3%), positive results were obtained for both markers. The two
markers agreed well on P. vivax positivity (kappa=0.71), although
the difference in PCR efficiency (McNemar’s test: P=0.026)
suggests a slightly higher sensitivity of the MS16 PCR.
Prevalence
The overall prevalence of P. vivax based on positivity by PCR
was 55%. The prevalence was lowest in children under 1.5 years at
44% and reached 62% in children aged 3 to 3.5 years. The
increase of prevalence by age at the time of the survey was
significant (P=0.005) largely driven by the lower prevalence in
children less than 1.5 years. Without this youngest age group no
evidence of a trend was observed. No major seasonal trend in P.
vivax prevalence was observed with the exception of a slight peak in
September (P=0.17).
Allelic diversity
In 1162 samples positive for P. vivax, 57 different msp1F3 and
103 different MS16 alleles were detected (Figures 1A and 1B).
Virtual heterozygocity HE was 97.8% for MS16, 88.1% for msp1F3
and 99.1% for msp1F3-MS16 haplotypes determined in single-
clone infections (Table 1). In 219 single clone infections from 148
patients, a total of 154 different haplotypes were observed with the
most common haplotype detected in only six individuals
(Figure 1C). We tested this data set for independence of the two
molecular markers. No linkage disequilibrium was observed
(IA
S=20.0001, P=0.53).
Multiplicity of infection
The MOI was determined for each marker separately, as well as
for both markers combined. In P. vivax positive samples, the mean
Table 1. Diversity and multiplicity of infection of P. vivax in Papua New Guinea.
No. of positive
samples No. of clones
Multiplicity of
infection Allelic richness
Virtual Hetero-
zygosity (HE)
msp1F3 1094 (79)* 2480 (173)* 2.27 57 (31)* 0.881 (0.874)*
MS16 1118 (80)* 2542 (175)* 2.27 103 (65)* 0.976 (0.977)*
combined 1162 NA** 2.69 NA** NA**
Single clone infections 219 (25)* 219 (25)* 1 154 (25)* 0.991 (0.96)*
*In brackets numbers for baseline only.
**NA=Not applicable.
doi:10.1371/journal.pntd.0001424.t001
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calculated from the maximal number of clones per sample by any
marker. Among samples for which positive results were obtained
from both markers, MOI was concordant in 38% (397/1050)
(kappa=0.17). A difference of one clone was observed in 38.5%
(404/1050) of samples. The frequency distribution of MOI plotted
separately for msp1F3 and MS16 was compared to the combined
MOI (Figure 2). A single marker slightly underestimated MOI.
Multiple clone infections were observed in 63% of all positive
samples by msp1F3 and in 61% by MS16. When results of both
markers were combined, the proportion of multiple clone
infections increased to 74% (Table S1). Likewise, the proportion
of samples with a MOI of 3 or higher was underestimated based
on a single marker. Of the 531 samples with a combined MOI
between 3 and 9, the combined MOI result was reproduced only
in 279 samples (52%) by msp1F3 alone and in 324 samples (61%)
by MS16 alone.
The mean MOI of P. vivax was associated with age. In children
up to 1.5 years the mean MOI was 2.4 increasing slightly up to 2.8
in children 3.5 to 4.5 years of age (Figure 3, P=0.02). If the
youngest children below 1.5 years were excluded, no significant
trend was observed (P=0.23). The increase of the proportion of
children bearing more than two clones was more pronounced
(Figure 4). In the 18 youngest children aged 300 to 400 days, we
observed a low MOI of 1.67 and only two children (11%) carried
more than 2 clones. There was no significant seasonal variation in
MOI (P=0.50).
Discussion
We have genotyped P. vivax parasites in a cohort of 268 children
from an area of Papua New Guinea with sympatric P. falciparum
and P. vivax with prevalences of 49.6% and 53.0% respectively in
this cohort at enrolment [8]. The ecology and epidemiology of P.
vivax differs from that of P. falciparum in several aspects. Parasite
densities are generally lower, which is likely to affect prevalence
data generated by both microscopically or molecular diagnosis
[28,29]. Gametocytes appear shortly after an infection is
established in a host [30], with implications for transmission and
the frequency of sexual recombination, and the occurrence of
relapses leads to appearance of new genotypes in the blood stream
independent of mosquito transmission.
Our genotyping enables the distinction of individual parasites
within the human host and thus the assessment of MOI. The mean
MOI for P. vivax in our cohort was 2.7 and 73.6% of samples
carried multiple clones (combined results from two independent
markers). This compares to a substantially lower P. falciparum MOI
of 1.5 in the same cohort determined by the marker msp2 and only
35.2% of samples carrying multiple clone infections [31].
The multiplicity of Plasmodium infections depends on a number
of factors including transmission intensity or the duration of
infection as the result of loss of infection and antimalarial
treatment. An additional factor, unique to P. vivax, contributes to
the number of blood stage infections circulating in the blood:
relapses of semi dormant liver stages. Previous studies have shown
that relapses often genetically differ from already present blood
stage parasites [32,33] and thus lead to increased MOI. As
Coartem does not clear liver stage parasites and the level of
treatment in our cohort was high, the combined effect of treatment
and relapses is likely to enhance differences between P. vivax and P.
falciparum MOI. In addition, as mosquitoes biting people
harbouring multi-clone infections are more likely to transmit
several clones concurrently [34,35], the higher MOI among P.
vivax blood-stage parasites will increase the likelihood that multi-
clone P. vivax infections are transmitted in a single mosquito bite.
Under intense transmission such as found in lowland PNG, the
MOI of P. vivax species increases with age, with the increase most
pronounced in children below 1.5 years. In an earlier study, no
evidence of differences between children aged 4 to 14 were found
[36]. This increase in early childhood may at least in part be
related to the increased exposed body surface with child growth
thus leading to higher rates of mosquito bites and consequently
risk of infection [37]. In addition, with rapidly increasing im-
munity fewer P. vivax infections may reach high densities which are
associated with febrile illness and antimalarial treatment [8] and
the average duration of a P. vivax infection may increase with age.
Figure 1. Allelic frequencies of P. vivax genotyping markers. Allelic frequencies of markers msp1F3 (A) and MS16 (B) and the combined
msp1F3-MS16 haplotypes (C). For msp1F3 and MS16 the frequencies of the 3 most frequent alleles and the respective sizes of the amplified product
are given.
doi:10.1371/journal.pntd.0001424.g001
Figure 2. Distribution of multiple clone infections. Distribution of
multiplicity of infection as detected by the markers msp1F3 and MS16
as well as both markers combined. Only samples with positive results
for both markers were included (n=1050).
doi:10.1371/journal.pntd.0001424.g002
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showed no pronounced seasonality, concurring with previous
findings using light microscopy and LDR detection [8]. In
contrast, the incidence of clinical disease increased in the wet
season [8]. The lack of annual fluctuations in P. vivax prevalence
and MOI observed in PNG is likely to be caused by relapses
during periods where there is less mosquito transmission.
The proportion of multiple-clone infections clearly differs from
observations from countries of lower P. vivax endemicity. We
observed polyclonal infections in three out of four samples. Even if
numbers cannot be compared directly to other studies using other
genotyping protocols (higher numbers of markers increase the
chance of observing several clones at least in one marker), this
proportion only reaches 11 to 49% in the Amazon [12,38], 55% in
Sri Lanka [11] but 73% in Myanmar [11].
The molecular markers msp1F3 and MS16 showed a high
degree of genetic diversity. While three msp1F3 alleles reached
frequencies above 10%, the distribution of MS16 alleles is more
homogenous with the highest frequency of 5%. The selected
markers are suitable for studies where high resolution discrimina-
tion between P. vivax clones is required, such as longitudinal
tracking of clones or discrimination between existing and incoming
infections. The probability of two individual clones sharing the
same 2-loci haplotype was below 1%. Analysing additional
polymorphic markers would lead only to a minimal improvement
of discrimination. As the mean MOI increases, the chance that
two clones within a host share the same haplotype increases.
Simulations indicate that mean MOI would be unlikely to be
substantially underestimated with either marker, unless the
mean MOI was greater than 6 (Amanda Ross, manuscript in
Figure 3. Boxplot of MOI by age group. The median is represented by the central line. The box represents the interquartile range from the 25
th
to 75
th centiles. The whiskers extend to the most extreme data point which is no more than 1.5 times the interquartile range from the box, points
beyond this are plotted individually.
doi:10.1371/journal.pntd.0001424.g003
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the genetic diversity of two P. falciparum markers, msp1 and msp2,
previously determined in the same cohort [22]. MS16 was highly
diverse in our cohort, and has been shown to be almost as diverse
in countries of lower P. vivax endemicity such as Peru [12] and
Vietnam [39] but was lower in Sri Lanka and Ethiopia [11].
In more than half of the samples, the number of clones detected
was discordant for the two markers. Three factors contribute to
such discrepancies, namely (i) differences in the discrimination
power of the two markers, (ii) imperfect detection of clones in
samples with low parasite densities and (iii) mutation of one of the
markers occurring within a host (Text S1). Given the high diversity
of both markers, we expect that limited discrimination power only
accounts for a small fraction of observed discrepancies. More
likely, low parasite densities around the detection limit will cause
imperfect detection of clones. In a previously published analysis of
clone detectability in the same set of samples, we have determined
the contribution of an additional blood sample collected 24 hours
later from the same children. This analysis showed that detection
of genotypes by PCR is equally imperfect for both species, P.
falciparum and P. vivax. Overall, 17 to 31% of all clones were missed
on a single day, and detection of clones was imperfect especially in
samples harboring a high number of concurrent clones [31]. In
addition, in serial dilutions of parasite DNA from field samples we
now show that at very low concentrations, MOI and allelic
composition differed between replicates. In particular minority
clones were lost. It is therefore very likely that such stochastic
amplification of genotypes also occurred in our samples.
Due to its antigenicity and surface exposed location, MSP1 is
considered a candidate for a malaria vaccine (reviewed in [13]).
We identified 57 MSP1F3 alleles with the 3 most abundant alleles
adding up to a frequency of 53%. The predominant alleles
maintained stable allelic frequencies throughout the study. In a
similar number of Papua New Guinean children, 27 haplotypes
were observed for another potential vaccine candidate, the Duffy
Binding Protein II (DBPII, XM_001615397). The 3 most frequent
DBPII alleles were present in 57% of infections [40]. These results
indicate high diversity of P. vivax antigens in PNG. With respect to
vaccine development based on PvMSP1, the allelic frequencies
generated in our genotyping study provide useful information on
genetic diversity of this antigen.
In summary, this study provides one of the first large data sets of
P. vivax genotypes from a highly endemic area. Our high resolution
typing technique accurately determined allelic frequencies and
clone multiplicity. This adds to the knowledge about P. vivax
epidemiology and may serve as reference data for high endemicity
P. vivax populations. The molecular parameters established could
be utilized as one of several measures for effective monitoring of
intervention and control of P. vivax, for surveillance and to
parameterize mathematical models of transmission dynamics [40].
Supporting Information
Table S1 Genotyping results from 1162 P. vivax positive
field samples using the markers msp1F3 and MS16. This
table contains the number of samples for MOI=1 to MOI=9 for
each marker separately and for the combination of both markers.
(PDF)
Text S1 Validation of Plasmodium vivax genotyping
based on msp1F3 and MS16 as molecular markers. This
text contains results from confirmation of multiplicity of infection
in field samples by genotyping additional molecular markers,
congruence of samples typed in duplicate, and detection of clones
in serial dilutions of DNA. This file contains Tables A–F and
Figures A and B.
(PDF)
Checklist S1 STROBE checklist.
(DOC)
Acknowledgments
We thank the study participants and their parents and guardians, and the
IMR field team.
Author Contributions
Conceived and designed the experiments: IF IM TAS PS PAZ CK.
Performed the experiments: CK BK. Analyzed the data: CK AR. Wrote
the paper: CK AR IF.
References
1. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, et al. (2010)
The international limits and population at risk of Plasmodium vivax trans-
mission in 2009. PLoS Negl Trop Dis 4: e774.
2. Mueller I, Bockarie M, Alpers M, Smith T (2003) The epidemiology of malaria
in Papua New Guinea. Trends in Parasitology 19: 253–259.
3. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, et al. (2008) A trial of
combination antimalarial therapies in children from Papua New Guinea.
N Engl J Med 359: 2545–2557.
4. Darlow B, Vrbova H, Gibney S, Jolley D, Stace J, et al. (1982) Sulfadoxine-
pyrimethamine for the treatment of acute malaria in children of Papua New Guinea.
II. Plasmodium vivax. Am J Trop Med Hyg 31: 10–13.
5. Mueller I, Genton B, Betuela I, Alpers MP (2010) Vaccines against malaria:
perspectives from Papua New Guinea. Hum Vaccin 6: 17–20.
6. Mueller I, Widmer S, Michel D, Maraga S, McNamara DT, et al. (2009)
High sensitivity detection of Plasmodium species reveals positive correlations
between infections of different species, shifts in age distribution and reduced
local variation in Papua New Guinea. Malar J 8: 41.
7. Muller I, Genton B, Rare L, Kiniboro B, Kastens W, et al. (2009) Three
different Plasmodium species show similar patterns of clinical tolerance of
malaria infection. Malar J 8: 158.
8. Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, et al. (2010) Differential
patterns of infection and disease with P. falciparum and P. vivax in young Papua
New Guinean children. PLoS One 5: e9047.
9. Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, et al. (2007) The risk
of malarial infections and disease in Papua New Guinean children. Am J Trop
Med Hyg 76: 997–1008.
Figure 4. Proportions of multiple clone infections by age
group. Proportion of children with P. vivax multiplicity of infection of 1,
2 and 3 to 9 by age. Results from two markers combined are shown.
Error bars show 95% confidence intervals.
doi:10.1371/journal.pntd.0001424.g004
Plasmodium vivax in Papua New Guinea
www.plosntds.org 6 December 2011 | Volume 5 | Issue 12 | e142410. Paul RE, Packer MJ, Walmsley M, Lagog M, Ranford-Cartwright LC, et al.
(1995) Mating patterns in malaria parasite populations of Papua New Guinea.
Science 269: 1709–1711.
11. Gunawardena S, Karunaweera ND, Ferreira MU, Phone-Kyaw M, Pollack RJ,
et al. (2010) Geographic structure of Plasmodium vivax: microsatellite analysis of
parasite populations from Sri Lanka, Myanmar, and Ethiopia. Am J Trop Med
Hyg 82: 235–242.
12. Van den Eede P, Van der Auwera G, Delgado C, Huyse T, Soto-Calle VE, et al.
(2010) Multilocus genotyping reveals high heterogeneity and strong local
population structure of the Plasmodium vivax population in the Peruvian
Amazon. Malar J 9: 151.
13. Galinski MR, Barnwell JW (2008) Plasmodium vivax: who cares? Malar J 7
Suppl 1: S9.
14. Tanabe K, Escalante A, Sakihama N, Honda M, Arisue N, et al. (2007) Recent
independent evolution of msp1 polymorphism in Plasmodium vivax and related
simian malaria parasites. Mol Biochem Parasitol 156: 74–79.
15. Zeyrek FY, Tachibana S, Yuksel F, Doni N, Palacpac N, et al. (2010) Limited
polymorphism of the Plasmodium vivax merozoite surface protein 1 gene in
isolates from Turkey. Am J Trop Med Hyg 83: 1230–1237.
16. Farooq U, Malla N, Dubey ML (2009) Polymorphism in merozoite surface
protein-1 gene in north & northwest Indian field isolates of Plasmodium vivax.
Indian J Med Res 130: 736–741.
17. Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, et al. (2008) Evaluation of
Plasmodium vivax genotyping markers for molecular monitoring in clinical
trials. J Infect Dis.
18. Genton B, Al Yaman F, Beck HP, Hii J, Mellor S, et al. (1995) The epidemiology
of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in
preparation for vaccine trials. I. Malariometric indices and immunity. Ann Trop
Med Parasitol 89: 359–376.
19. Genton B, Al Yaman F, Beck HP, Hii J, Mellor S, et al. (1995) The epidemiology
of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in
preparation for vaccine trials. II. Mortality and morbidity. Ann Trop Med
Parasitol 89: 377–390.
20. Smith T, Hii JL, Genton B, Muller I, Booth M, et al. (2001) Associations of peak
shifts in age–prevalence for human malarias with bednet coverage. Trans R Soc
Trop Med Hyg 95: 1–6.
21. Kasehagen LJ, Mueller I, McNamara DT, Bockarie MJ, Kiniboro B, et al.
(2006) Changing patterns of Plasmodium blood-stage infections in the Wosera
region of Papua New Guinea monitored by light microscopy and high
throughput PCR diagnosis. Am J Trop Med Hyg 75: 588–596.
22. Schoepflin S, Valsangiacomo F, Lin E, Kiniboro B, Mueller I, et al. (2009)
Comparison of Plasmodium falciparum allelic frequency distribution in different
endemic settings by high-resolution genotyping. Malar J 8: 250.
23. McNamara DT, Kasehagen LJ, Grimberg BT, Cole-Tobian J, Collins WE, et al.
(2006) Diagnosing infection levels of four human malaria parasite species by a
polymerase chain reaction/ligase detection reaction fluorescent microsphere-
based assay. Am J Trop Med Hyg 74: 413–421.
24. Havryliuk T, Ferreira MU (2009) A closer look at multiple-clone Plasmodium
vivax infections: detection methods, prevalence and consequences. Mem Inst
Oswaldo Cruz 104: 67–73.
25. StataCorp. College Station T (2007) Stata Statistical Software: Release 10.
26. Lunn DJ, Thomas A, Best N, Spiegelhalter D (2000) WinBUGS - A Bayesian
modelling framework: Concepts, structure, and extensibility. Statistics and
Computing 10: 13.
27. LIAN website. Available: http://adenine.biz.fh-weihenstephan.de/cgi-bin/lian/
lian.cgi.pl. Accessed 2011 Nov 7.
28. Rodulfo H, De Donato M, Mora R, Gonzalez L, Contreras CE (2007)
Comparison of the diagnosis of malaria by microscopy, immunochromatogra-
phy and PCR in endemic areas of Venezuela. Braz J Med Biol Res 40: 535–543.
29. Harris I, Sharrock WW, Bain LM, Gray KA, Bobogare A, et al. (2010) A large
proportion of asymptomatic Plasmodium infections with low and sub-
microscopic parasite densities in the low transmission setting of Temotu
Province, Solomon Islands: challenges for malaria diagnostics in an elimination
setting. Malar J 9: 254.
30. Garnham PCC (1966) Malaria Parasites And Other Heamosporidia. Oxford:
Blackwell Scientific Publications.
31. Koepfli C, Schoepflin S, Bretscher M, Lin E, Kiniboro B, et al. (2011) How
much remains undetected? Probability of molecular detection of human
plasmodia in the field. PLoS ONE 6: e19010.
32. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q (2007) Relapses of
Plasmodium vivax infection result from clonal hypnozoites activated at
predetermined intervals. J Infect Dis 195: 934–941.
33. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, et al.
(2007) Relapses of Plasmodium vivax infection usually result from activation of
heterologous hypnozoites. J Infect Dis 195: 927–933.
34. Rosenberg R, Rungsiwongse J, Kangsadalampai S, Sattabongkot J,
Suwanabun N, et al. (1992) Random mating of natural Plasmodium populations
demonstrated from individual oocysts. Mol Biochem Parasitol 53: 129–133.
35. Babiker HA, Ranford-Cartwright LC, Currie D, Charlwood JD, Billingsley P,
et al. (1994) Random mating in a natural population of the malaria parasite
Plasmodium falciparum. Parasitology 109(Pt 4): 413–421.
36. Bruce MC, Galinski MR, Barnwell JW, Donnelly CA, Walmsley M, et al. (2000)
Genetic diversity and dynamics of plasmodium falciparum and P. vivax
populations in multiply infected children with asymptomatic malaria infections
in Papua New Guinea. Parasitology 121(Pt 3): 257–272.
37. Smith T, Maire N, Dietz K, Killeen GF, Vounatsou P, et al. (2006) Relationship
between the entomologic inoculation rate and the force of infection for
Plasmodium falciparum malaria. Am J Trop Med Hyg 75: 11–18.
38. Ferreira MU, Karunaweera ND, da Silva-Nunes M, da Silva NS, Wirth DF,
et al. (2007) Population structure and transmission dynamics of Plasmodium
vivax in rural Amazonia. J Infect Dis 195: 1218–1226.
39. Van den Eede P, Erhart A, Van der Auwera G, Van Overmeir C, Thang ND,
et al. (2010) High complexity of Plasmodium vivax infections in symptomatic
patients from a rural community in central Vietnam detected by microsatellite
genotyping. Am J Trop Med Hyg 82: 223–227.
40. The malERA Consultative Group on Modeling (2011) A research agenda for
malaria eradication: modeling. PLoS Med 8: e1000403.
Plasmodium vivax in Papua New Guinea
www.plosntds.org 7 December 2011 | Volume 5 | Issue 12 | e1424